10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2018-11-14 (Q3 2018) | Holdings: 97 | Value: $15.2B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seattle Genetics, Inc. | 25.93% | $3.9B | +33.61% | +114.49% | |||
| INCY - Incyte Corporation | 15.59% | $2.4B | +3.57% | +33.95% | +38.01% | ||
| BGNE - BeiGene, Ltd. | 13.57% | $2.1B | +96.95% | +6.04% | +58.99% | ||
| ALXN - Alexion Pharmaceuticals, Inc. | 7.83% | $1.2B | +11.83% | -6.36% | |||
| GHDX - Genomic Health, Inc. | 6.38% | $968.4M | +10.19% | ||||
| BMRN - BioMarin Pharmaceutical Inc. | 4.84% | $735.3M | -36.26% | +3.16% | -17.64% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | Add 4% ($25.1M) | 3.89% | $590.4M | +23.97% | +33.62% | +164.94% | |
| AMRN - Amarin Corporation plc | Add 50% ($185.5M) | 3.65% | $554.3M | -96.61% | +3.21% | +40.39% | |
| MDGL - Madrigal Pharmaceuticals, Inc. | 1.65% | $250.4M | +95.21% | -4.07% | -29.44% | ||
| ASND - Ascendis Pharma A/S | 1.32% | $201.1M | +190.89% | +31.19% | +100.98% | ||
| HRTX - Heron Therapeutics, Inc. | 1.05% | $159.1M | -93.14% | +0.73% | -21.30% | ||
| NVTA - Invitae Corporation | 0.93% | $140.5M | +31.75% | +53.57% | |||
| DBVT - DBV Technologies S.A. | 0.82% | $123.7M | -94.84% | -53.21% | -52.53% | ||
| MRTX - Mirati Therapeutics, Inc. | 0.78% | $118.4M | +95.32% | +158.10% | |||
| NBIX - Neurocrine Biosciences, Inc. | 0.77% | $116.1M | +41.40% | -3.08% | +29.94% | ||
| BCRX - BioCryst Pharmaceuticals, Inc. | Add 8% ($8.3M) | 0.76% | $115.2M | +54.90% | +29.68% | -74.78% | |
| ARRY1 - Array BioPharma Inc. | 0.57% | $86.0M | |||||
| SAGE - Sage Therapeutics, Inc. | Reduce 7% $(6.5M) | 0.53% | $80.2M | -93.97% | +50.26% | +36.62% | |
| RYTM - Rhythm Pharmaceuticals, Inc. | 0.52% | $79.0M | +137.53% | +16.34% | -15.41% | ||
| CERS - Cerus Corporation | 0.51% | $77.5M | -74.80% | +28.37% | -11.31% | ||
| ARGX - argenx SE | Add 6% ($4.4M) | 0.51% | $77.3M | +515.15% | +36.00% | +49.55% | |
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.50% | $76.5M | +61.13% | +4.18% | -61.48% | ||
| ONCE - Spark Therapeutics, Inc. | 0.50% | $75.5M | +34.65% | +182.75% | |||
| GWPH - GW Pharmaceuticals plc | Add 23% ($12.9M) | 0.45% | $68.5M | +17.05% | -15.68% | ||
| CBAY - CymaBay Therapeutics, Inc. | 0.36% | $54.5M | +9.46% | -40.37% | |||
| PRNB - Principia Biopharma Inc. | New Purchase | 0.34% | $52.2M | +25.73% | +24.69% | ||
| TCDA - Tricida, Inc. | 0.32% | $48.9M | -25.08% | +9.16% | |||
| ECYT - Endocyte, Inc. | Add 12% ($4.8M) | 0.30% | $45.3M | ||||
| IDRA - Idera Pharmaceuticals, Inc. | Reduce 87% $(301.3M) | 0.28% | $43.1M | -62.78% | -70.37% | ||
| N/A - Corsicanto II Designated Activity Company | New Purchase | 0.27% | $41.7M | ||||
| INSM - Insmed Incorporated | Add 165% ($23.3M) | 0.25% | $37.4M | +321.58% | +63.66% | +22.61% | |
| NLTX - Aquinox Pharmaceuticals, Inc. | 0.21% | $32.0M | |||||
| ABEO - Abeona Therapeutics Inc. | 0.18% | $28.0M | -96.59% | -9.43% | -68.31% | ||
| SLDB - Solid Biosciences Inc. | 0.18% | $27.7M | -99.29% | -73.51% | -88.35% | ||
| GLPG - Galapagos NV | Reduce 9% $(2.6M) | 0.18% | $26.7M | -71.73% | +1.36% | +80.61% | |
| XNCR - Xencor, Inc. | Reduce 31% $(10.5M) | 0.15% | $23.5M | -78.37% | -1.41% | -2.70% | |
| MYOK - MyoKardia, Inc. | Reduce 18% $(4.9M) | 0.15% | $23.3M | -21.77% | +0.70% | ||
| MRUS - Merus N.V. | 0.15% | $22.9M | +310.77% | -16.78% | +15.09% | ||
| QURE - uniQure N.V. | 0.15% | $22.0M | -51.15% | +26.47% | +78.49% | ||
| SGMO - Sangamo Therapeutics, Inc. | 0.14% | $21.8M | -95.11% | -7.47% | -0.95% | ||
| CMTA - Clementia Pharmaceuticals Inc. | Add 62% ($8.3M) | 0.14% | $21.6M | -1.87% | |||
| ZYME - Zymeworks Inc. | 0.14% | $20.6M | -9.07% | +24.98% | +187.51% | ||
| AIMT - Aimmune Therapeutics, Inc. | 0.12% | $18.4M | -15.41% | -6.81% | |||
| N/A - Neurocrine Biosciences, Inc. | New Purchase | 0.11% | $17.1M | ||||
| BLCM - Bellicum Pharmaceuticals, Inc. | Reduce 35% $(8.7M) | 0.11% | $16.5M | -26.79% | -79.61% | ||
| N/A - BioMarin Pharmaceutical Inc. | New Purchase | 0.10% | $15.8M | ||||
| BOLD - Audentes Therapeutics, Inc. | 0.10% | $15.6M | |||||
| CFRX - ContraFect Corporation | 0.10% | $14.8M | -78.00% | -85.44% | |||
| AGLE - Aeglea BioTherapeutics, Inc. | New Purchase | 0.09% | $13.3M | -92.15% | +7.19% | +0.51% | |
| N/A - BioMarin Pharmaceutical Inc. | New Purchase | 0.08% | $12.6M | ||||
| N/A - BioMarin Pharmaceutical Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| BLUE - bluebird bio, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| PHXM - ERYTECH Pharma S.A. | Reduce 100% | 0.00% | $0.00 | ||||
| HALO - Halozyme Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | +216.27% | +11.81% | +24.08% | |
| NTLA - Intellia Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | -7.96% | -17.56% | -21.63% | |
| N/A - Novavax, Inc. | Reduce 100% | 0.00% | $0.00 | ||||